Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of UI059 vs UIC202201 in Healthy Volunteers
NCT06393881Phase 1Not yet recruiting
- Sponsor
- Korea United Pharm Inc.
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rabeprazole and sodium bicarbonate in gastroesophageal reflux disease (GERD), sponsored by Korea United Pharm Inc. Primary endpoints: Area Under the Concentration-Time Curve at Steady State over the Dosing Interval and Percent Decrease from Baseline in Integrated Gastric Acidity at Day 7. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
rabeprazolesodium bicarbonate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06393881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393881.